Writing Group Disclosures.
| Writing Group Member |
Employment | Research Grant |
Other Research Support |
Speakers’ Bureau/ Honoraria |
Expert Witness |
Ownership Interest |
Consultant/ Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| Jennifer L. Hall | University of Minnesota | NIH* | None | None | None | None | JACC (associate editor)†; JCTR (editor)† | None |
| John J. Ryan | University of Utah | None | None | None | None | None | None | None |
| Bruce E. Bray | University of Utah | None | None | None | None | None | None | None |
| Candice Brown | Wake Forest School of Medicine | NIH/NINDS* | None | None | None | None | None | None |
| David Lanfear | Henry Ford Hospital | None | None | None | None | None | None | None |
| L. Kristin Newby | Duke Clinical Research Institute | David H Murdock Institute for Business and Culture (MURDOCK Study)†; NIA*; PCORI*; Google Life Sciences†; Sanofi* | None | None | None | None | None | None |
| Mary V. Relling | St. Jude Children’s Research Hospital, Pharmaceutical Sciences | None | None | None | None | None | None | None |
| Neil J. Risch | University of California, San Francisco, Institute for Human Genetics | None | None | None | None | None | None | None |
| Dan M. Roden | Vanderbilt University School of Medicine | None | None | None | None | None | None | None |
| Stanley Y. Shaw | Massachusetts General Hospital Center for Systems Biology | Merck† | None | None | None | None | None | None |
| James E. Tcheng | Duke University Medical Center, Duke Clinical Research Institute | None | None | None | None | None | None | None |
| Jessica Tenenbaum | Duke University | None | None | None | None | None | None | None |
| Thomas N. Wang | Vanderbilt University School of Medicine | None | None | None | None | None | None | None |
| William S. Weintraub | Christiana Care Health System | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.